menu search

ALPMF / Iveric Bio stock surges on Astellas Pharma takeover deal

Iveric Bio stock surges on Astellas Pharma takeover deal
Iveric Bio Inc shares climbed 16% to $38.01 on Monday after the US drugmaker agreed to be acquired by Japan's Astellas Pharma for $40 per share in cash or total consideration of about $5.9 billion.   Iveric's primary asset is avacincaptad pegol (ACP) which is currently in trials for treating geographic atrophy, the advanced stage of macular degeneration, a common cause of vision loss in the elderly. Read More
Posted: May 1 2023, 15:13
Author Name: Proactive Investors
Views: 112233

ALPMF News  

Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript

Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call November 1, 2023 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, more_horizontal

Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 6, 2023

Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript

Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call August 1, 2023 4:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, A more_horizontal

Iveric Bio stock surges on Astellas Pharma takeover deal

By Proactive Investors
May 1, 2023

Iveric Bio stock surges on Astellas Pharma takeover deal

Iveric Bio Inc shares climbed 16% to $38.01 on Monday after the US drugmaker agreed to be acquired by Japan's Astellas Pharma for $40 per share in ca more_horizontal


Search within

Pages Search Results: